Laura Fogliatto

Laura Fogliatto

Auto-generated profile, based on publicly available information

Laura Fogliatto

Santa Casa de Porto Alegre, Hospital das Clínicas de Porto Alegre, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2002 in Transplantation Proceedings
Verified
Journal Article
Closed access
VGV.D Garcia
V.D Garcia
JBJ.S Bonamigo-Filho
J.S Bonamigo-Filho
JNJ Neumann
J Neumann
LFL Fogliatto
L Fogliatto
AGA.M Gaiger
A.M Gaiger
SRS Roithmann
S Roithmann

14 October 2012 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
DKDayane B. Koshiyama
Dayane B. Koshiyama
MCMarcelo E. Z. Capra
Marcelo E. Z. Capra
GPGiorgio A. Paskulin
Giorgio A. Paskulin
RRRafael Fabiano Machado Rosa
Rafael Fabiano Machado Rosa
COCeres A. V. Oliveira
Ceres A. V. Oliveira
PZPaulo Ricardo Gazzola Zen
Paulo Ricardo Gazzola Zen

3 June 2024 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
MDMarcia Torresan Delamain
Marcia Torresan Delamain
ACAna Carolina Ferreira Cardoso
Ana Carolina Ferreira Cardoso
FPFernando Vieira Pericole
Fernando Vieira Pericole
SASérgio Shusterschitz da Silva Araújo
Sérgio Shusterschitz da Silva Araújo
LFLaura Fogliatto
Laura Fogliatto
VCVivienne Castilho
Vivienne Castilho
Introduction RTXM83, a biosimilar of rituximab, was approved after physicochemical, functional, non-clinical, and clinical studies demonstrated their similarity; these studies included RTXM83-AC-01-11, a multicentric double-blind international prospective pivotal study. Long-term data on biosimilars can potentially elucidate their clinical robustness and facilitate their broader adoption. Methods In this retrospective observational study, we analyzed a dataset from a Brazilian cohort previously randomized in the RTXM83-AC-01-11 study followed by the assessment of long-term outcomes in an observational extension phase from randomization in the RTXM83-AC-01–11 study to the last recorded evaluation. Patients with diffuse large B cell lymphoma (DLBCL) received either reference rituximab (R) or RTXM83 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as adjuvant treatment. Results The median follow-up period was 77.0 months. Patients with initial DLBCL stages III and IV comprised 50% of the R-CHOP group and 40% of the biosimilar group. Five (18.5%) patients, including two RTXM83-CHOP-treated and three R-CHOP-treated individuals, experienced late adverse events (AEs) of interest. No new safety signs were established. At the final assessment, the progression-free survival (PFS) rates were 93.3% and 50.0% in the RTXM83-CHOP and R-CHOP groups, respectively. Median PFS was not achieved in the RTXM83-CHOP group, which was 40.5 months in the R-CHOP group. The overall survival (OS) rates were 100% and 66.7% in the RTXM83-CHOP and R-CHOP groups, respectively. The median OS was not reached in any group. Conclusion This study demonstrated the long-term safety and effectiveness of RTXM83 in treating DLBCL; outcomes comparable to those of the reference product and potentially improved access to treatment have been indicated. However, further research with more diverse patient groups can validate these findings and advocate the broader adoption of biosimilars in cancer care. Trial Registration ClinicalTrials.gov Identifier: NCT04928573. June 16, 2021, “retrospectively registered”.